PT  - JOURNAL ARTICLE
AU  - Jean-François Dufour
AU  - Cyrielle Caussy
AU  - Rohit Loomba
TI  - Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
AID  - 10.1136/gutjnl-2019-319104
DP  - 2020 May 06
TA  - Gut
PG  - gutjnl-2019-319104
4099  - http://gut.bmj.com/content/early/2020/05/17/gutjnl-2019-319104.short
4100  - http://gut.bmj.com/content/early/2020/05/17/gutjnl-2019-319104.full
AB  - Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.